News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

St. Jude Medical (STJ) Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System


5/14/2013 10:11:12 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced enrollment of the first patient in the EnligHTN III trial. This study will evaluate the safety and performance of the new second-generation EnligHTN™ Renal Denervation System in patients with drug-resistant, uncontrolled hypertension.The next-generation system utilizes the proven multi-electrode catheter paired with a new generator that features a high-tech, icon-friendly, touch screen user interface that provides simultaneous ablations using four electrodes. This advancement reduces total ablation time from approximately 24 minutes to four minutes. With its unique non-occlusive basket design, each placement of the ablation catheter using the EnligHTN system administers a predictable treatment pattern while allowing for continuous blood flow to the kidney throughout the procedure. Additionally, the new second-generation EnligHTN generator allows physicians to easily view and record procedure information.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES